Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment

Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. common cause of endocrinopathies such thyroid disease and adrenal insufficiency (AI). AI has been most commonly reported during active treatment cycles with pembrolizumab, well quickly after the termination treatment. However, we describe case pembrolizumab-induced onset at eight months following discontinuation discuss prompt when diagnosed.